Heron Therapeutics, Inc. (HRTX) Given Consensus Recommendation of “Buy” by Analysts

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) have been given a consensus rating of “Buy” by the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $29.56.

Several equities research analysts have recently weighed in on HRTX shares. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the stock a “buy” rating in a report on Thursday, October 26th. Jefferies Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Wednesday, August 16th. Northland Securities started coverage on shares of Heron Therapeutics in a report on Wednesday, September 27th. They issued an “outperform” rating and a $40.00 target price on the stock. Noble Financial reaffirmed a “buy” rating and issued a $24.00 target price on shares of Heron Therapeutics in a report on Friday, October 6th. Finally, BidaskClub lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 18th.

A number of large investors have recently modified their holdings of the business. Janus Henderson Group PLC grew its holdings in Heron Therapeutics by 2.2% during the 3rd quarter. Janus Henderson Group PLC now owns 5,767,495 shares of the biotechnology company’s stock worth $93,145,000 after acquiring an additional 126,039 shares during the last quarter. Vanguard Group Inc. grew its holdings in Heron Therapeutics by 11.8% during the 2nd quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock worth $29,036,000 after acquiring an additional 221,362 shares during the last quarter. Rubric Capital Management LP grew its holdings in Heron Therapeutics by 11.8% during the 3rd quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock worth $30,685,000 after acquiring an additional 200,000 shares during the last quarter. State Street Corp grew its holdings in Heron Therapeutics by 30.7% during the 1st quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock worth $26,822,000 after acquiring an additional 420,113 shares during the last quarter. Finally, Balyasny Asset Management LLC grew its holdings in Heron Therapeutics by 2.1% during the 2nd quarter. Balyasny Asset Management LLC now owns 1,221,403 shares of the biotechnology company’s stock worth $16,916,000 after acquiring an additional 24,688 shares during the last quarter.

Shares of Heron Therapeutics (HRTX) traded up $0.65 during mid-day trading on Thursday, hitting $17.60. 1,295,910 shares of the stock were exchanged, compared to its average volume of 819,861. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $18.40. The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The business had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. equities research analysts forecast that Heron Therapeutics will post -3.42 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Heron Therapeutics, Inc. (HRTX) Given Consensus Recommendation of “Buy” by Analysts” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/30/heron-therapeutics-inc-hrtx-given-consensus-recommendation-of-buy-by-analysts.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply